Stock Research for SNSS

SNSS
Current Price

$6.4000


Latest Update: 2018-02-20 16:00:00

High
$ 6.4100
Low
$ 6.3700
Close
$ 6.3700
Volume
4589
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

SNSS Stock Chart & Research Data

The SNSS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SNSS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SNSS Due diligence Resources & Stock Charts

The SNSS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SNSS Detailed Price Forecast - CNN Money CNN View SNSS Detailed Summary - Google Finance
Yahoo View SNSS Detailed Summary - Yahoo! Finance Zacks View SNSS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View SNSS Trends & Analysis - Trade-Ideas Barrons View SNSS Major Holders - Barrons
NASDAQ View SNSS Call Transcripts - NASDAQ Seeking View SNSS Breaking News & Analysis - Seeking Alpha
Spotlight View SNSS Annual Report - CompanySpotlight.com OTC Report View SNSS OTC Short Report - OTCShortReport.com
TradeKing View SNSS Fundamentals - TradeKing Charts View SNSS SEC Filings - Bar Chart
WSJ View Historical Prices for SNSS - The WSJ Morningstar View Performance/Total Return for SNSS - Morningstar
MarketWatch View the Analyst Estimates for SNSS - MarketWatch CNBC View the Earnings History for SNSS - CNBC
StockMarketWatch View the SNSS Earnings - StockMarketWatch MacroAxis View SNSS Buy or Sell Recommendations - MacroAxis
Bullish View the SNSS Bullish Patterns - American Bulls Short Pains View SNSS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View SNSS Stock Mentions - StockTwits PennyStocks View SNSS Stock Mentions - PennyStockTweets
Twitter View SNSS Stock Mentions - Twitter Invest Hub View SNSS Investment Forum News - Investor Hub
Yahoo View SNSS Stock Mentions - Yahoo! Message Board Seeking Alpha View SNSS Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for SNSS - SECform4.com Insider Cow View Insider Transactions for SNSS - Insider Cow
CNBC View SNSS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SNSS - OTC Markets
Yahoo View Insider Transactions for SNSS - Yahoo! Finance NASDAQ View Institutional Holdings for SNSS - NASDAQ


Stock Charts

FinViz View SNSS Stock Insight & Charts - FinViz.com StockCharts View SNSS Investment Charts - StockCharts.com
BarChart View SNSS Stock Overview & Charts - BarChart Trading View View SNSS User Generated Charts - Trading View


Latest Financial News for SNSS

Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
Posted on Wednesday February 07, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018-- Sunesis Pharmaceuticals, Inc. today announced that H. Ward Wolff has been appointed to the Sunesis Board of Directors. Wolff brings over 40 years of finance ...


Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017
Posted on Tuesday December 05, 2017

-Company announces vecabrutinib as generic name for SNS-062-. -Event on December 9 in Atlanta, GA with Slide Webcast-. SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017-- Sunesis Pharmaceuticals, Inc. today announced ...


Sunesis Pharmaceuticals Announces Change in Leadership
Posted on Monday December 04, 2017

-Daniel Swisher Resigns as CEO Effective End of 2017; t o Remain with Sunesis as a Strategic Advisor-. -Board Member Dayton Misfeldt Appointed Interim CEO Effective January 2018; Board Starting Retained ...


Edited Transcript of SNSS earnings conference call or presentation 2-Nov-17 6:00pm GMT
Posted on Thursday November 30, 2017

Q3 2017 Sunesis Pharmaceuticals Inc Earnings Call


Sunesis Pharmaceuticals (NASDAQ:SNSS) Upgraded to Sell by ValuEngine
Week Herald - Dec 11, 2017
Sunesis Pharmaceuticals, Inc. logo ValuEngine upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a strong sell rating to a sell rating in a research report sent to investors on Wednesday, February 7th.
Analysts See $-0.25 EPS for Sunesis Pharmaceuticals, Inc. (SNSS); Compass ... - NormanObserver.com

Sunesis Pharmaceuticals: Overhang Cleared For This Oncology Turnaround Story
Seeking Alpha - Oct 26, 2017
The bull thesis remains intact and strengthened, with initial data from several cohorts to hopefully be presented in the second quarter of 2018.

Sunesis Pharmaceuticals: SNS-062 Could Be The Company's Salvation
Seeking Alpha - Aug 29, 2017
Reversable, non-covalent Bruton's Tyrosine Kinase-inhibitor SNS-062 could be the company's last remaining hope. Intriguing preclinical data supports progressing the asset into trials.

Healthcare Industry Trends And Its Impact On Sunesis Pharmaceuticals Inc ...
Simply Wall St - Feb 17, 2018
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS), a US$206.52M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector ...
Sunesis Pharmaceuticals (SNSS) Stock Rating Lowered by Zacks Investment Research - The Ledger Gazette
Sunesis Pharmaceuticals (NASDAQ:SNSS) Upgraded by ValuEngine to “Sell” - Dispatch Tribunal

Enter a stock symbol to view the stock details.